The costs of prostatectomy for benign prostatic hyperplasia

Area of Science:

• Urology
• Health Economics
• Health Services Research

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men, often requiring surgical intervention.
• Surgical treatment costs for BPH encompass initial procedures, complication management, and reoperations.
• Understanding the economic impact of BPH surgery is crucial for healthcare resource allocation.

Purpose of the Study:

• To estimate the total costs associated with surgical treatment for benign prostatic hyperplasia (BPH).
• To analyze costs related to initial prostatectomy, postsurgical complications, and reoperations within one year.
• To quantify the economic burden of BPH surgical management.

Main Methods:

• Utilized claims data from a 5% random sample of Medicare beneficiaries.
• Identified 14,480 men who underwent prostatectomy for BPH between 1986-1987.
• Calculated mean total inpatient costs and total expected costs including readmissions for complications and reoperations.

Main Results:

• Mean total inpatient costs were $6,501 for transurethral prostatectomy and $10,223 for open prostatectomy.
• Readmission rates for complications or reoperation were 6.8% for transurethral and 5.2% for open procedures.
• Total expected costs within one year were $6,823 for transurethral and $10,477 for open prostatectomy.

Conclusions:

• Surgical treatment of benign prostatic hyperplasia (BPH) represents a substantial economic burden.
• Costs associated with complications and reoperations significantly contribute to the overall economic impact.
• Findings underscore the importance of considering the full economic implications of BPH surgical interventions.